<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000657510"><TermName>pralatrexate</TermName><TermPronunciation>(PRA-luh-TREK-sayt)</TermPronunciation><TermDefinition><DefinitionText>A drug used in the treatment of peripheral T-cell lymphoma (a fast-growing form of non-Hodgkin lymphoma). It is also being studied in the treatment of other types of cancer. Pralatrexate may block the growth of cancer cells and cause them to die. It is a type of dihydrofolate reductase (DHFR) inhibitor. Also called FOLOTYN.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000725641" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;pralatrexate&quot;" language="en" id="_3"/><MediaLink ref="CDR0000725642" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;pralatrexato&quot;" language="es" id="_4"/><SpanishTermName>pralatrexato</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa para el tratamiento del linfoma de células T periféricas (forma de linfoma no Hodgkin de crecimiento rápido). También está en estudio para el tratamiento de otros tipos de cáncer. El pralatrexato podría impedir el crecimiento de células cancerosas y hacer que se destruyan. Es un tipo de inhibidor de la dihidrofolato reductasa (DHFR). También se llama FOLOTYN.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2009-10-27</DateFirstPublished><RelatedInformation><RelatedDrugSummaryRef href="CDR0000656656">Pralatrexate</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
